Welcome to our dedicated page for Biomarin Pharmaceutical news (Ticker: BMRN), a resource for investors and traders seeking the latest updates and insights on Biomarin Pharmaceutical stock.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a global rare disease biotechnology company focused on medicines for genetically defined conditions. This news page aggregates company announcements, press releases and event updates so readers can follow how BioMarin’s strategy, pipeline and commercial portfolio evolve over time.
Recent communications from BioMarin highlight its emphasis on Enzyme Therapies and Skeletal Conditions business units, as well as its work with ROCTAVIAN, a gene therapy for hemophilia A. The company issues news on topics such as financial results, long-term guidance, corporate strategy, business development transactions, clinical data presentations and regulatory milestones for its therapies.
Examples of news themes include updates on VOXZOGO in achondroplasia and other skeletal conditions, progress with PALYNZIQ in phenylketonuria, development of BMN 401 for ENPP1 deficiency and other pipeline programs in rare genetic diseases. BioMarin also reports on strategic partnerships, such as digital and data collaborations, and on planned acquisitions intended to expand and diversify its rare disease portfolio.
Investors and followers of BMRN can use this page to review earnings announcements, conference presentations, investor day materials and product-specific updates released through newswires. By checking this feed regularly, readers can see how BioMarin describes its growth priorities, clinical milestones and capital allocation decisions across its rare disease franchises.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced that the European Medicines Agency (EMA) has granted accelerated assessment for valoctocogene roxaparvovec, aimed at treating adults with severe hemophilia A. This expedited review process is expected to shorten the evaluation timeline, with a Committee for Medicinal Products for Human Use (CHMP) opinion anticipated in the first half of 2022. BioMarin plans to submit a Marketing Authorization Application (MAA) in June 2021, including 52 weeks of Phase 3 GENEr8-1 trial data.
BioMarin Pharmaceutical has shared a significant update regarding its investigational gene therapy valoctocogene roxaparvovec for severe hemophilia A. The latest data shows sustained treatment benefits over five years, with participants remaining off prophylactic Factor VIII treatment. The mean annualized bleed rate in year five was 0.7, representing a 95% reduction from baseline. The company plans to submit a Marketing Authorization Application in Europe in June 2021 and a Biologics License Application in the U.S. in Q2 2022, contingent on favorable study results.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced participation in two virtual conferences, with live audio webcasts available for investors. The webcasts can be accessed at biomarin.com. An archived version will also be accessible post-conference. BioMarin focuses on developing therapies for rare disorders, boasting a portfolio of six commercial products and various clinical candidates. For more details, visit their website.
BioMarin Pharmaceutical announced three oral and three poster presentations for its investigational gene therapy, valoctocogene roxaparvovec, at the ASGCT Virtual 2021 Annual Meeting. These presentations enhance the understanding of the therapy's potential for treating adults with severe hemophilia A. The company plans to submit a Marketing Authorization Application in Europe and a Biologics License Application in the U.S. by mid-2022, contingent on favorable study results. BioMarin also maintains a strong focus on manufacturing capabilities, aiming to produce 10,000 doses per year.
BioMarin Pharmaceutical (NASDAQ: BMRN) announced participation in two virtual investor conferences on May 3, 2021. Management will present, with an audio webcast available live, and an archived version will be accessible on their website for a limited time post-conference. BioMarin specializes in developing therapies for serious rare disorders, with a portfolio that includes six commercial products and numerous candidates in various stages of development. More information can be found on their official site.
BioMarin Pharmaceutical reported Q1 2021 financial results, showing a 3% decline in total revenues to $486 million compared to Q1 2020. Net product revenues decreased 4% to $417.8 million, with significant drops in Kuvan revenues (-42%) due to generic competition. GAAP net income fell to $17.4 million from $81.4 million, impacted by a prior year asset sale. Positive cash flow of $113.5 million and promising product pipelines, including potential approvals for vosoritide and valoctocogene roxaparvovec, suggest a pivotal year ahead.
BioMarin has partnered with the Allen Institute to develop gene therapies targeting rare genetic diseases of the central nervous system. This collaboration will leverage unique gene delivery technologies, specifically engineered adeno-associated viruses (AAVs) that enhance precision in gene therapy applications. BioMarin will receive exclusive rights for research, development, and commercialization of these therapies. While financial terms were not disclosed, both organizations aim to advance clinical therapy candidates that can significantly impact patient outcomes in the CNS therapeutic area.
BioMarin Pharmaceutical presented data at the 2021 ACMG Annual Clinical Genetics Meeting regarding its investigational treatment, vosoritide, for achondroplasia. The Phase 2 extension study revealed a sustained mean increase in annual growth velocity of 1.35 cm/year over 60 months, with a height Z-score improvement of 0.78. Vosoritide was well tolerated, demonstrating no new adverse events. Additionally, the Lifetime Impact of Achondroplasia in Europe study highlighted increased medical burdens for individuals with achondroplasia, emphasizing the need for ongoing clinical assessments.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will conduct a conference call and webcast on April 29, 2021, at 4:30 p.m. ET to discuss its first quarter 2021 financial results and provide a business update. The call will be hosted by CEO Jean-Jacques Bienaimé. Interested parties can join via the BioMarin website. A replay will also be available for a week after the call. BioMarin specializes in therapies for serious rare genetic diseases, with a portfolio of six commercial products and several candidates in development.
BioMarin Pharmaceutical (NASDAQ: BMRN) presented long-term data at ENDO21 showing sustained efficacy of vosoritide in treating achondroplasia. After two years of treatment, children exhibited a mean annual growth velocity (AGV) improvement: 4.28 cm/year at baseline, 5.71 cm/year after one year, and 5.65 cm/year after two years. Retention of participants was high at 93%. Vosoritide, generally well tolerated with mild adverse events, is under review by the FDA and EMA, with a PDUFA action date of August 20, 2021. Additional data may reset this to November 2021.